Cargando…
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody-drug conjugates are monoclonal antibodies attached to biologically active drugs through chemical linkers that deliver and release cytotoxic agents at the tumor site, reducing the likelihood of systemic exposure and therefore toxicity. Currently, there are about 110 ongoing studies implement...
Autores principales: | Wolska-Washer, Anna, Robak, Tadeusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399172/ https://www.ncbi.nlm.nih.gov/pubmed/30649747 http://dx.doi.org/10.1007/s40264-018-0775-7 |
Ejemplares similares
-
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023) -
Toll-like receptors and their role in carcinogenesis and anti-tumor treatment
por: Wolska, Anna, et al.
Publicado: (2008) -
Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies
por: Wolska-Washer, Anna, et al.
Publicado: (2022) -
Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
por: Fisher, J. Edward
Publicado: (2021) -
Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)